WS
LGND icon

Wedbush Securities’s Ligand Pharmaceuticals LGND Stock Holding History

Wedbush Securities’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Sell
1,081
-2
-0.2% -$471 0.01% 876
2026
Q1 		$216K Hold
1,083
– – 0.01% 1086
2025
Q4 		$205K Sell
1,083
-50
-4% -$9.61K 0.01% 1102
2025
Q3 		$201K Buy
+1,133
New +$168K 0.01% 1078

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wedbush Securities's LGND Position: Q2 2026 in Review

Wedbush Securities reduced its Ligand Pharmaceuticals (LGND) stake by 0.18% in Q2 2026, selling an estimated $471 and leaving 1,081 shares worth $342K. The position accounts for 0.01% of the portfolio, ranked #876.

Wedbush Securities first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Wedbush Securities held 1,081 shares of Ligand Pharmaceuticals worth $342K as of Q2 2026.
  • Wedbush Securities sold 2 Ligand Pharmaceuticals shares in Q2 2026, an estimated $471.
  • Ligand Pharmaceuticals made up 0.01% of Wedbush Securities's portfolio in Q2 2026, its #876 holding.
  • Wedbush Securities first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.